Efficacy of DMARDs and methylprednisolone treatment on the gene expression levels of HSPA5, MMD, and non-coding RNAs MALAT1, H19, miR-199a-5p, and miR-1-3p, in patients with rheumatoid arthritis

• Published in: International immunopharmacology Vol. 108; p. 108878
• Main Authors: Mahmoudi, Zahra, Karamali, Negin, Roghani, Seyed Askar, Assar, Shirin, Pournazari, Mehran, Soufivand, Parviz, Salari, Farhad, Rezaiemanesh, Alireza
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2022
• Subjects: DMARDs; HSPA5; MMD; ncRNAs; Rheumatoid arthritis; MEG3; lncRNA; JNK; FACS; DMARDs; Anti-CCP; ncRNA; ncRNAs; ETS1; TNF; TH17 cell; AUC; NF-κB; HIF1-α; IRE1; miRNA; PAQR1; WBC; cDNA; ROC curve; RT-qPCR; DAS28; HSPA5; circRNA; MMD; ESR; MACS; STAT3; mPRED; MAPK; NEAT1; ER; PBMC; IL-6; RA; ACR; PICSAR; APC; Rheumatoid arthritis; EULAR; MALAT1; ATF6; XBP1s

•MALAT1 and H19 may be candidates as potential biomarkers in rheumatoid arthritis.•MALAT1 and H19 positively correlated with MMD and RA severity.•DMARDs plus mPRED were not effective in reducing HSPA5 and MMD gene expression. Rheumatoid arthritis (RA) is a systemic autoimmune disease with chronic in...